Vigil Neuroscience to Present in Upcoming June Investor Conferences
Vigil Neuroscience, a clinical-stage biotech firm focused on neurodegenerative diseases, announced its participation in two upcoming investor conferences. The company's President and CEO, Ivana Magovčević-Liebisch, and Chief Science Officer, David Gray, will join a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 a.m. ET. Additionally, Ivana Magovčević-Liebisch will present at the Goldman Sachs Global Healthcare Conference on June 11, 2024, at 10:40 a.m. ET. Live webcasts will be available on Vigil's website, with archived versions accessible for 90 days.
- Participation in high-profile investor conferences enhances company visibility.
- Direct engagement with investors and analysts may boost investor confidence.
- Availability of live and archived webcasts increases transparency and accessibility.
- No specific updates on clinical trials or business development were provided.
- Potential investor fatigue with frequent conference attendances without substantial new information.
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.
- Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th at 9:30 a.m. E.T.
- Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11th at 10:40 a.m. E.T.
The live webcasts from the events will be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. Archived webcasts will be available for approximately 90 days following the presentation.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
MacDougall Advisors
mmcgrath@macdougall.bio
FAQ
When will Vigil Neuroscience participate in the Jefferies Global Healthcare Conference?
What time is Vigil Neuroscience presenting at the Goldman Sachs Global Healthcare Conference?
How can I view the webcasts of Vigil Neuroscience's presentations?
Who will represent Vigil Neuroscience at the investor conferences?
